{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T06:30:25Z","timestamp":1790317825965,"version":"4.1.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,1,10]],"date-time":"2017-01-10T00:00:00Z","timestamp":1484006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2017,1,10]],"date-time":"2017-01-10T00:00:00Z","timestamp":1484006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"DOI":"10.1038\/tp.2016.252","type":"journal-article","created":{"date-parts":[[2017,1,10]],"date-time":"2017-01-10T15:23:56Z","timestamp":1484061836000},"page":"e995-e995","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration"],"prefix":"10.1038","volume":"7","author":[{"given":"K","family":"H\u00f6glund","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Kern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Zettergren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"B\u00f6rjesson-Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Skoog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,10]]},"reference":[{"key":"BFtp2016252_CR1","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0140-6736(06)69113-7","volume":"368","author":"K Blennow","year":"2006","unstructured":"Blennow K, de Leon MJ, Zetterberg H . Alzheimer's disease. Lancet 2006; 368: 387\u2013403.","journal-title":"Lancet"},{"key":"BFtp2016252_CR2","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1202753","volume":"367","author":"RJ Bateman","year":"2012","unstructured":"Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012; 367: 795\u2013804.","journal-title":"N Engl J Med"},{"key":"BFtp2016252_CR3","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/ana.21559","volume":"65","author":"AM Fagan","year":"2009","unstructured":"Fagan AM, Head D, Shah AR, Marcus D, Mintun M, Morris JC et al. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol 2009; 65: 176\u2013183.","journal-title":"Ann Neurol"},{"key":"BFtp2016252_CR4","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1001\/archgenpsychiatry.2011.155","volume":"69","author":"P Buchhave","year":"2012","unstructured":"Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O . Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 2012; 69: 98\u2013106.","journal-title":"Arch Gen Psychiatry"},{"key":"BFtp2016252_CR5","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/S1474-4422(07)70178-3","volume":"6","author":"B Dubois","year":"2007","unstructured":"Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6: 734\u2013746.","journal-title":"Lancet Neurol"},{"key":"BFtp2016252_CR6","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/ana.20730","volume":"59","author":"AM Fagan","year":"2006","unstructured":"Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006; 59: 512\u2013519.","journal-title":"Ann Neurol"},{"key":"BFtp2016252_CR7","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1212\/01.WNL.0000046581.81650.D0","volume":"60","author":"D Strozyk","year":"2003","unstructured":"Strozyk D, Blennow K, White LR, Launer LJ . CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 2003; 60: 652\u2013656.","journal-title":"Neurology"},{"key":"BFtp2016252_CR8","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrneurol.2010.4","volume":"6","author":"K Blennow","year":"2010","unstructured":"Blennow K, Hampel H, Weiner M, Zetterberg H . Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010; 6: 131\u2013144.","journal-title":"Nat Rev Neurol"},{"key":"BFtp2016252_CR9","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/acn3.81","volume":"1","author":"N Mattsson","year":"2014","unstructured":"Mattsson N, Insel PS, Landau S, Jagust W, Donohue M, Shaw LM et al. Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease. Ann Clin Transl Neurol 2014; 1: 534\u2013543.","journal-title":"Ann Clin Transl Neurol"},{"key":"BFtp2016252_CR10","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1001\/jamaneurol.2014.1358","volume":"71","author":"S Palmqvist","year":"2014","unstructured":"Palmqvist S, Zetterberg H, Blennow K, Vestberg S, Andreasson U, Brooks DJ et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid beta-amyloid 42: a cross-validation study against amyloid positron emission tomography. JAMA Neurol 2014; 71: 1282\u20131289.","journal-title":"JAMA Neurol"},{"key":"BFtp2016252_CR11","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/emmm.200900048","volume":"1","author":"AM Fagan","year":"2009","unstructured":"Fagan AM, Mintun MA, Shah AR, Aldea P, Roe CM, Mach RH et al. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med 2009; 1: 371\u2013380.","journal-title":"EMBO Mol Med"},{"issue":"4 Suppl","key":"BFtp2016252_CR12","doi-asserted-by":"publisher","first-page":"S85","DOI":"10.1016\/S0197-4580(97)00062-6","volume":"18","author":"H Braak","year":"1997","unstructured":"Braak H, Braak E . Diagnostic criteria for neuropathologic assessment of Alzheimer's disease. Neurobiol Aging 1997; 18 (4 Suppl): S85\u2013S88.","journal-title":"Neurobiol Aging"},{"key":"BFtp2016252_CR13","doi-asserted-by":"crossref","unstructured":"Fagan AM, Xiong C, Jasielec MS, Bateman RJ, Goate AM, Benzinger TL et al. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. Sci Transl Med 2014; 6 226ra30.","DOI":"10.1126\/scitranslmed.3007901"},{"key":"BFtp2016252_CR14","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.1523\/JNEUROSCI.16-14-04491.1996","volume":"16","author":"T Gomez-Isla","year":"1996","unstructured":"Gomez-Isla T, Price JL, McKeel DW Jr., Morris JC, Growdon JH, Hyman BT . Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci 1996; 16: 4491\u20134500.","journal-title":"J Neurosci"},{"key":"BFtp2016252_CR15","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1097\/00005072-199812000-00009","volume":"57","author":"CM Hulette","year":"1998","unstructured":"Hulette CM, Welsh-Bohmer KA, Murray MG, Saunders AM, Mash DC, McIntyre LM . Neuropathological and neuropsychological changes in \"normal\" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol 1998; 57: 1168\u20131174.","journal-title":"J Neuropathol Exp Neurol"},{"key":"BFtp2016252_CR16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1001\/archneur.63.1.38","volume":"63","author":"WR Markesbery","year":"2006","unstructured":"Markesbery WR, Schmitt FA, Kryscio RJ, Davis DG, Smith CD, Wekstein DR . Neuropathologic substrate of mild cognitive impairment. Arch Neurol 2006; 63: 38\u201346.","journal-title":"Arch Neurol"},{"key":"BFtp2016252_CR17","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1385\/JMN:17:2:101","volume":"17","author":"JC Morris","year":"2001","unstructured":"Morris JC, Price JL . Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J Mol Neurosci 2001; 17: 101\u2013118.","journal-title":"J Mol Neurosci"},{"key":"BFtp2016252_CR18","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1001\/archneur.58.9.1395","volume":"58","author":"JL Price","year":"2001","unstructured":"Price JL, Ko AI, Wade MJ, Tsou SK, McKeel DW, Morris JC . Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch Neurol 2001; 58: 1395\u20131402.","journal-title":"Arch Neurol"},{"key":"BFtp2016252_CR19","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","volume":"12","author":"VL Villemagne","year":"2013","unstructured":"Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 2013; 12: 357\u2013367.","journal-title":"Lancet Neurol"},{"key":"BFtp2016252_CR20","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","volume":"13","author":"B Dubois","year":"2014","unstructured":"Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol 2014; 13: 614\u2013629.","journal-title":"Lancet Neurol"},{"key":"BFtp2016252_CR21","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1001\/archneurol.2012.1608","volume":"69","author":"PT Kotzbauer","year":"2012","unstructured":"Kotzbauer PT, Cairns NJ, Campbell MC, Willis AW, Racette BA, Tabbal SD et al. Pathologic accumulation of alpha-synuclein and Abeta in Parkinson disease patients with dementia. Arch Neurol 2012; 69: 1326\u20131331.","journal-title":"Arch Neurol"},{"key":"BFtp2016252_CR22","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1001\/archneurol.2009.224","volume":"66","author":"N Ghoshal","year":"2009","unstructured":"Ghoshal N, Cali I, Perrin RJ, Josephson SA, Sun N, Gambetti P et al. Codistribution of amyloid beta plaques and spongiform degeneration in familial Creutzfeldt-Jakob disease with the E200K-129M haplotype. Arch Neurol 2009; 66: 1240\u20131246.","journal-title":"Arch Neurol"},{"key":"BFtp2016252_CR23","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nature15369","volume":"525","author":"Z Jaunmuktane","year":"2015","unstructured":"Jaunmuktane Z, Mead S, Ellis M, Wadsworth JD, Nicoll AJ, Kenny J et al. Evidence for human transmission of amyloid-beta pathology and cerebral amyloid angiopathy. Nature 2015; 525: 247\u2013250.","journal-title":"Nature"},{"key":"BFtp2016252_CR24","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1001\/jamaneurol.2013.4847","volume":"71","author":"YT Hong","year":"2014","unstructured":"Hong YT, Veenith T, Dewar D, Outtrim JG, Mani V, Williams C et al. Amyloid imaging with carbon 11-labeled Pittsburgh compound B for traumatic brain injury. JAMA Neurol 2014; 71: 23\u201331.","journal-title":"JAMA Neurol"},{"key":"BFtp2016252_CR25","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1001\/archneur.65.11.1509","volume":"65","author":"HJ Aizenstein","year":"2008","unstructured":"Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008; 65: 1509\u20131517.","journal-title":"Arch Neurol"},{"issue":"Pt 5","key":"BFtp2016252_CR26","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1093\/brain\/awp062","volume":"132","author":"CR Jack Jr.","year":"2009","unstructured":"Jack CR Jr., Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009; 132 (Pt 5): 1355\u20131365.","journal-title":"Brain"},{"issue":"Pt 11","key":"BFtp2016252_CR27","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1093\/brain\/awm238","volume":"130","author":"KE Pike","year":"2007","unstructured":"Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007; 130 (Pt 11): 2837\u20132844.","journal-title":"Brain"},{"key":"BFtp2016252_CR28","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1016\/j.neuropsychologia.2008.02.008","volume":"46","author":"VL Villemagne","year":"2008","unstructured":"Villemagne VL, Pike KE, Darby D, Maruff P, Savage G, Ng S et al. Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia 2008; 46: 1688\u20131697.","journal-title":"Neuropsychologia"},{"issue":"Pt 9","key":"BFtp2016252_CR29","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1093\/brain\/awv181","volume":"138","author":"T Skillback","year":"2015","unstructured":"Skillback T, Farahmand BY, Rosen C, Mattsson N, Nagga K, Kilander L et al. Cerebrospinal fluid tau and amyloid-beta1-42 in patients with dementia. Brain 2015; 138 (Pt 9): 2716\u20132731.","journal-title":"Brain"},{"key":"BFtp2016252_CR30","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.3233\/JAD-143156","volume":"45","author":"DS Bouvier","year":"2015","unstructured":"Bouvier DS, Murai KK . Synergistic actions of microglia and astrocytes in the progression of Alzheimer's disease. J Alzheimers Dis 2015; 45: 1001\u20131014.","journal-title":"J Alzheimers Dis"},{"key":"BFtp2016252_CR31","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.neuron.2005.10.028","volume":"48","author":"JR Cirrito","year":"2005","unstructured":"Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC et al. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron 2005; 48: 913\u2013922.","journal-title":"Neuron"},{"key":"BFtp2016252_CR32","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/1750-1326-6-63","volume":"6","author":"RM Koffie","year":"2011","unstructured":"Koffie RM, Hyman BT, Spires-Jones TL . Alzheimer's disease: synapses gone cold. Mol Neurodegener 2011; 6: 63.","journal-title":"Mol Neurodegener"},{"key":"BFtp2016252_CR33","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/j.jalz.2014.10.009","volume":"11","author":"H Kvartsberg","year":"2014","unstructured":"Kvartsberg H, Duits FH, Ingelsson M, Andreasen N, Ohrfelt A, Andersson K et al. Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. Alzheimers Dement 2014; 11: 1180\u20131190.","journal-title":"Alzheimers Dement"},{"key":"BFtp2016252_CR34","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1373\/clinchem.2008.104497","volume":"54","author":"JM Lee","year":"2008","unstructured":"Lee JM, Blennow K, Andreasen N, Laterza O, Modur V, Olander J et al. The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients. Clin Chem 2008; 54: 1617\u20131623.","journal-title":"Clin Chem"},{"key":"BFtp2016252_CR35","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3233\/JAD-2012-120787","volume":"33","author":"B Olsson","year":"2013","unstructured":"Olsson B, Hertze J, Lautner R, Zetterberg H, Nagga K, Hoglund K et al. Microglial markers are elevated in the prodromal phase of Alzheimer's disease and vascular dementia. J Alzheimers Dis 2013; 33: 45\u201353.","journal-title":"J Alzheimers Dis"},{"key":"BFtp2016252_CR36","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1159\/000362164","volume":"4","author":"C Rosen","year":"2014","unstructured":"Rosen C, Andersson CH, Andreasson U, Molinuevo JL, Bjerke M, Rami L et al. Increased levels of chitotriosidase and YKL-40 in cerebrospinal fluid from patients with Alzheimer's disease. Dement Geriatr Cogn Dis Extra 2014; 4: 297\u2013304.","journal-title":"Dement Geriatr Cogn Dis Extra"},{"key":"BFtp2016252_CR37","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S1474-4422(06)70355-6","volume":"5","author":"O Hansson","year":"2006","unstructured":"Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L . Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006; 5: 228\u2013234.","journal-title":"Lancet Neurol"},{"key":"BFtp2016252_CR38","first-page":"163","volume":"26","author":"B Steen","year":"1993","unstructured":"Steen B, Djurfeldt H . The gerontological and geriatric population studies in Gothenburg, Sweden. Z Gerontol 1993; 26: 163\u2013169.","journal-title":"Z Gerontol"},{"key":"BFtp2016252_CR39","doi-asserted-by":"publisher","first-page":"214","DOI":"10.3109\/02813439709035031","volume":"15","author":"C Bengtsson","year":"1997","unstructured":"Bengtsson C, Ahlqwist M, Andersson K, Bjorkelund C, Lissner L, Soderstrom M . The Prospective Population Study of Women in Gothenburg, Sweden, 1968-69 to 1992-93. A 24-year follow-up study with special reference to participation, representativeness, and mortality. Scand J Prim Health Care 1997; 15: 214\u2013219.","journal-title":"Scand J Prim Health Care"},{"key":"BFtp2016252_CR40","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1046\/j.1600-0447.2003.00260.x","volume":"109","author":"I Skoog","year":"2004","unstructured":"Skoog I . Psychiatric epidemiology of old age: the H70 study\u2014the NAPE lecture 2003. Acta Psychiatr Scand 2004; 109: 4\u201318.","journal-title":"Acta Psychiatr Scand"},{"key":"BFtp2016252_CR41","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/JGP.0b013e3181860051","volume":"17","author":"B Karlsson","year":"2009","unstructured":"Karlsson B, Klenfeldt IF, Sigstrom R, Waern M, Ostling S, Gustafson D et al. Prevalence of social phobia in non-demented elderly from a swedish population study. Am J Geriatr Psychiatry 2009; 17: 127\u2013135.","journal-title":"Am J Geriatr Psychiatry"},{"key":"BFtp2016252_CR42","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.neurobiolaging.2006.01.008","volume":"28","author":"X Guo","year":"2007","unstructured":"Guo X, Waern M, Sjogren K, Lissner L, Bengtsson C, Bjorkelund C et al. Midlife respiratory function and Incidence of Alzheimer's disease: a 29-year longitudinal study in women. Neurobiol Aging 2007; 28: 343\u2013350.","journal-title":"Neurobiol Aging"},{"key":"BFtp2016252_CR43","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1056\/NEJM199301213280301","volume":"328","author":"I Skoog","year":"1993","unstructured":"Skoog I, Nilsson L, Palmertz B, Andreasson LA, Svanborg A . A population-based study of dementia in 85-year-olds. N Engl J Med 1993; 328: 153\u2013158.","journal-title":"N Engl J Med"},{"key":"BFtp2016252_CR44","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR . \"Mini-mental state\". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189\u2013198.","journal-title":"J Psychiatr Res"},{"key":"BFtp2016252_CR45","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1097\/JGP.0b013e31813c6b6c","volume":"15","author":"J Wancata","year":"2007","unstructured":"Wancata J, Borjesson-Hanson A, Ostling S, Sjogren K, Skoog I . Diagnostic criteria influence dementia prevalence. Am J Geriatr Psychiatry 2007; 15: 1034\u20131045.","journal-title":"Am J Geriatr Psychiatry"},{"key":"BFtp2016252_CR46","unstructured":"American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders. 3rd edn. American Psychiatric Disorders: Washington DC, 1987."},{"key":"BFtp2016252_CR47","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/BF02815140","volume":"26","author":"K Blennow","year":"1995","unstructured":"Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E . Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol Chem Neuropathol 1995; 26: 231\u2013245.","journal-title":"Mol Chem Neuropathol"},{"key":"BFtp2016252_CR48","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0304-3940(00)01036-3","volume":"285","author":"E Vanmechelen","year":"2000","unstructured":"Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, Sjogren M et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 2000; 285: 49\u201352.","journal-title":"Neurosci Lett"},{"key":"BFtp2016252_CR49","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1001\/archneur.56.6.673","volume":"56","author":"N Andreasen","year":"1999","unstructured":"Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B et al. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol 1999; 56: 673\u2013680.","journal-title":"Arch Neurol"},{"key":"BFtp2016252_CR50","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13195-015-0124-3","volume":"7","author":"H Kvartsberg","year":"2015","unstructured":"Kvartsberg H, Portelius E, Andreasson U, Brinkmalm G, Hellwig K, Lelental N et al. Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer's disease patients and healthy controls. Alzheimers Res Ther 2015; 7: 40.","journal-title":"Alzheimers Res Ther"},{"key":"BFtp2016252_CR51","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0006-8993(03)03219-0","volume":"987","author":"N Norgren","year":"2003","unstructured":"Norgren N, Rosengren L, Stigbrand T . Elevated neurofilament levels in neurological diseases. Brain Res 2003; 987: 25\u201331.","journal-title":"Brain Res"},{"key":"BFtp2016252_CR52","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1159\/000366119","volume":"4","author":"M Bjerke","year":"2014","unstructured":"Bjerke M, Jonsson M, Nordlund A, Eckerstrom C, Blennow K, Zetterberg H et al. Cerebrovascular biomarker profile is related to white matter disease and ventricular dilation in a LADIS substudy. Dement Geriatr Cogn Dis Extra 2014; 4: 385\u2013394.","journal-title":"Dement Geriatr Cogn Dis Extra"},{"key":"BFtp2016252_CR53","doi-asserted-by":"publisher","first-page":"e39358","DOI":"10.1371\/journal.pone.0039358","volume":"7","author":"A Pillai","year":"2012","unstructured":"Pillai A, Bruno D, Sarreal AS, Hernando RT, Saint-Louis LA, Nierenberg J et al. Plasma BDNF levels vary in relation to body weight in females. PLoS ONE 2012; 7: e39358.","journal-title":"PLoS ONE"},{"key":"BFtp2016252_CR54","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1159\/000358800","volume":"14","author":"E Portelius","year":"2014","unstructured":"Portelius E, Soininen H, Andreasson U, Zetterberg H, Persson R, Karlsson G et al. Exploring Alzheimer molecular pathology in Down's syndrome cerebrospinal fluid. Neurodegener Dis 2014; 14: 98\u2013106.","journal-title":"Neurodegener Dis"},{"key":"BFtp2016252_CR55","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1212\/WNL.0000000000002423","volume":"86","author":"H Wellington","year":"2016","unstructured":"Wellington H, Paterson RW, Portelius E, Tornqvist U, Magdalinou N, Fox NC et al. Increased CSF neurogranin concentration is specific to Alzheimer disease. Neurology 2016; 86: 829\u2013835.","journal-title":"Neurology"},{"key":"BFtp2016252_CR56","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3389\/fphys.2012.00385","volume":"3","author":"VS Moulle","year":"2012","unstructured":"Moulle VS, Cansell C, Luquet S, Cruciani-Guglielmacci C . The multiple roles of fatty acid handling proteins in brain. Front Physiol 2012; 3: 385.","journal-title":"Front Physiol"},{"key":"BFtp2016252_CR57","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1515\/CCLM.2005.135","volume":"43","author":"MM Pelsers","year":"2005","unstructured":"Pelsers MM, Glatz JF . Detection of brain injury by fatty acid-binding proteins. Clin Chem Lab Med 2005; 43: 802\u2013809.","journal-title":"Clin Chem Lab Med"},{"key":"BFtp2016252_CR58","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.3233\/JAD-2010-101293","volume":"22","author":"D Chiasserini","year":"2010","unstructured":"Chiasserini D, Parnetti L, Andreasson U, Zetterberg H, Giannandrea D, Calabresi P et al. CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease. J Alzheimers Dis 2010; 22: 1281\u20131288.","journal-title":"J Alzheimers Dis"},{"key":"BFtp2016252_CR59","doi-asserted-by":"publisher","first-page":"673","DOI":"10.3233\/JAD-121384","volume":"34","author":"B Olsson","year":"2013","unstructured":"Olsson B, Hertze J, Ohlsson M, Nagga K, Hoglund K, Basun H et al. Cerebrospinal fluid levels of heart fatty acid binding protein are elevated prodromally in Alzheimer's disease and vascular dementia. J Alzheimers Dis 2013; 34: 673\u2013679.","journal-title":"J Alzheimers Dis"},{"key":"BFtp2016252_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnagi.2011.00001","volume":"3","author":"C Rosen","year":"2011","unstructured":"Rosen C, Mattsson N, Johansson PM, Andreasson U, Wallin A, Hansson O et al. Discriminatory analysis of biochip-derived protein patterns in CSF and plasma in neurodegenerative diseases. Front Aging Neurosci 2011; 3: 1.","journal-title":"Front Aging Neurosci"},{"key":"BFtp2016252_CR61","doi-asserted-by":"crossref","unstructured":"Bjerke M, Kern S, Blennow K, Zetterberg H, Waern M, Borjesson-Hanson A et al. Cerebrospinal fluid fatty acid-binding protein 3 is related to dementia development in a population-based sample of older adult women followed for 8 years. J Alzheimers Dis 2015.","DOI":"10.3233\/JAD-150525"},{"key":"BFtp2016252_CR62","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1750-1326-8-39","volume":"8","author":"RS Desikan","year":"2013","unstructured":"Desikan RS, Thompson WK, Holland D, Hess CP, Brewer JB, Zetterberg H et al. Heart fatty acid binding protein and Abeta-associated Alzheimer's neurodegeneration. Mol Neurodegener 2013; 8: 39.","journal-title":"Mol Neurodegener"},{"key":"BFtp2016252_CR63","doi-asserted-by":"publisher","first-page":"89ra","DOI":"10.1126\/scitranslmed.3002156","volume":"3","author":"JM Castellano","year":"2011","unstructured":"Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW et al. Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci Transl Med 2011; 3: 89ra\u201357.","journal-title":"Sci Transl Med"},{"key":"BFtp2016252_CR64","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.neuron.2009.06.026","volume":"63","author":"J Kim","year":"2009","unstructured":"Kim J, Basak JM, Holtzman DM . The role of apolipoprotein E in Alzheimer's disease. Neuron 2009; 63: 287\u2013303.","journal-title":"Neuron"},{"key":"BFtp2016252_CR65","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.biopsych.2004.07.021","volume":"56","author":"T Sunderland","year":"2004","unstructured":"Sunderland T, Mirza N, Putnam KT, Linker G, Bhupali D, Durham R et al. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. Biol Psychiatry 2004; 56: 670\u2013676.","journal-title":"Biol Psychiatry"},{"key":"BFtp2016252_CR66","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1212\/01.WNL.0000128088.08695.05","volume":"62","author":"JA Prince","year":"2004","unstructured":"Prince JA, Zetterberg H, Andreasen N, Marcusson J, Blennow K . APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42. Neurology 2004; 62: 2116\u20132118.","journal-title":"Neurology"},{"key":"BFtp2016252_CR67","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1001\/jamapsychiatry.2014.1060","volume":"71","author":"R Lautner","year":"2014","unstructured":"Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Palsson E et al. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. JAMA Psychiatry 2014; 71: 1183\u20131191.","journal-title":"JAMA Psychiatry"},{"key":"BFtp2016252_CR68","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1212\/WNL.53.7.1488","volume":"53","author":"N Andreasen","year":"1999","unstructured":"Andreasen N, Minthon L, Clarberg A, Davidsson P, Gottfries J, Vanmechelen E et al. Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample. Neurology 1999; 53: 1488\u20131494.","journal-title":"Neurology"},{"key":"BFtp2016252_CR69","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1001\/jamaneurol.2015.1285","volume":"72","author":"CL Sutphen","year":"2015","unstructured":"Sutphen CL, Jasielec MS, Shah AR, Macy EM, Xiong C, Vlassenko AG et al. Longitudinal cerebrospinal fluid biomarker changes in preclinical Alzheimer disease during middle age. JAMA Neurol 2015; 72: 1029\u20131042.","journal-title":"JAMA Neurol"},{"key":"BFtp2016252_CR70","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.neurobiolaging.2010.04.007","volume":"31","author":"CC Rowe","year":"2010","unstructured":"Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010; 31: 1275\u20131283.","journal-title":"Neurobiol Aging"},{"key":"BFtp2016252_CR71","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1212\/WNL.0000000000001015","volume":"83","author":"T Skillback","year":"2014","unstructured":"Skillback T, Farahmand B, Bartlett JW, Rosen C, Mattsson N, Nagga K et al. CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. Neurology 2014; 83: 1945\u20131953.","journal-title":"Neurology"}],"updated-by":[{"DOI":"10.1038\/s41398-018-0301-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,11,19]],"date-time":"2018-11-19T00:00:00Z","timestamp":1542585600000}}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/tp2016252.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tp2016252","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tp2016252.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T16:34:28Z","timestamp":1671726868000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/tp2016252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,10]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,1]]}},"alternative-id":["BFtp2016252"],"URL":"https:\/\/doi.org\/10.1038\/tp.2016.252","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,10]]},"assertion":[{"value":"10 March 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KB and HZ are co-founders of Brain Biomarker Solutions in Gothenburg AB, a GU Venture-based platform company at the University of Gothenburg. KB has served as a consultant for Eli Lilly, Novartis, Roche Diagnostics, and Sanofi-Aventis and at Advisory Boards for Amgen and IBL International, and given lectures for Fujirebio Europe and Lundbeck. KB\u2019s research team has received grants for collaborative research projects from Eli Lilly and Roche Diagnostics. KH, AZ, SK, IS and AB have nothing to disclose. As primary authors, KH and SK have had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}